Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late
2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) …

In December 2019, the novel betacoronavirus Severe Acute Respiratory Disease
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …

The durability of infection-induced SARS-CoV-2 immunity has major implications for
reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a
global pandemic, and cases continue to rise. Most infected individuals experience mildly …

Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS …

We conducted a serological study to define correlates of immunity against SARS-CoV-2.
Compared to those with mild coronavirus disease 2019 (COVID-19) cases, individuals with …

Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) mount a humoral immune response to the virus within a few weeks of infection, but …

Responsible for more than 4.9 million deaths so far, COVID-19, caused by SARS-CoV-2, is
instigating devastating effects on the global health care system whose impacts could be …

It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular
administration designed to produce humoral and cell mediated immune responses …

Introduction The longevity of antibody levels against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and the duration of immunity are current topics of major …